Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
CGD NOTES
August 18, 2023
The World Health Organization (WHO) declared the end of the Public Health Emergency of International Concern (PHEIC) for COVID-19 on May 5 and for mpox on May 11, 2023. Throughout its use, the meaning of the PHEIC has been muddled. We call for a new, objective epidemic scale that better communicates...
POLICY PAPERS
August 07, 2023
CGD conducted a landscaping exercise to better understand the current landscape of organizations headquartered in sub-Saharan Africa that boast impact evaluation capacity. The resulting database is intended as a resource for funders looking to advance locally led development; to help facilitate coor...
CGD NOTES
June 05, 2023
The World Bank’s lending function is important and irreplaceable. But providing countries with an important source of financing and investing in evidence do not have to be in tension. The role of evaluation should shift from an assessment function to one in which evaluation is a central tool of pro...
CGD NOTES
March 20, 2023
With global challenges high on the international agenda and financing set to increase in the coming years, a big push on evidence, backed by dedicated resources, is essential. This note makes the case for a reinvigorated evidence agenda to boost the impact of financing for development and global pub...
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...
POLICY PAPERS
October 04, 2022
In this paper, we report the results of a horizon-scanning exercise to source opportunities for global health R&D investment—that is, high-value potential biomedical innovations which are currently underfunded but which could be transformative for health, quality of life, and health security in LMIC...
BRIEFS
July 19, 2022
This brief summarizes the final report of the working group. The report collates resources and insights on progress in implementing and using impact evaluations for decision making and proposes five ways to improve impact evaluation funding and practice, directed to the development community
BRIEFS
July 19, 2022
This brief lays out how the World Bank can more systematically embed impact evaluation and related data and evidence functions into programming, implementation, and country support. The recommendations are based on working group discussions, consultations with experts currently and formerly at the W...